Drug Trial Radar · NCT07209813
GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Nov 14, 2025
Primary completion
Sep 30, 2027
Study completion Oct 31, 2027
Sponsor
- Lead sponsor
- Beijing Gene Key Life Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Oct 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, open-label, controlled Phase 2 study in patients with unresectable hepatocellular carcinoma (uHCC). The purpose of this study is to compare the efficacy and safety of GKL-006 Injection in combination with transarterial chemoembolization (TACE) versus TACE alone.
Conditions
- Hepatocellular Carcinoma (HCC)
- Unresectable Hepatocellular Cancer
Interventions
GKL-006 InjectionDrug
An iNKT cell therapy
TACEProcedure
A standard locoregional therapy for hepatocellular carcinoma
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) Assessed by Independent Review Committee Based on mRECISTTime frame: Up to approximately 18 months
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
302 Hospital
Beijing, Beijing Municipality, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Recruiting
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China · Recruiting
Zhongda Hospital
Nanjing, Jiangsu, China · Recruiting
Nanjing Second Hospital
Nanjing, Jiangsu, China · Recruiting
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.